Shareholders in Salix Pharmaceuticals (Nasdaq: SLXP) and InKine Pharmaceutical have voted to approve the merger of the two firms in a deal worth some $190 million.
The merger was announced in June. The companies announced shareholder approval on Friday.
InKine will operate as a subsidiary of Raleigh-based Salix.
Salix: www.salix.com
